SG11202008767XA - Antibodies against mica and/or micb and uses thereof - Google Patents

Antibodies against mica and/or micb and uses thereof

Info

Publication number
SG11202008767XA
SG11202008767XA SG11202008767XA SG11202008767XA SG11202008767XA SG 11202008767X A SG11202008767X A SG 11202008767XA SG 11202008767X A SG11202008767X A SG 11202008767XA SG 11202008767X A SG11202008767X A SG 11202008767XA SG 11202008767X A SG11202008767X A SG 11202008767XA
Authority
SG
Singapore
Prior art keywords
micb
antibodies against
against mica
mica
antibodies
Prior art date
Application number
SG11202008767XA
Inventor
Michelle Renee Kuhne
Alan J Korman
Haichun Huang
Yiming Yin
Robert F Graziano
Natalie A Bezman
Pavel Strop
Richard Y Huang
Guodong Chen
Mohan Srinivasan
Peter Sung Keun Lee
Gamze Ozlem Camdere
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202008767XA publication Critical patent/SG11202008767XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202008767XA 2018-03-23 2019-03-22 Antibodies against mica and/or micb and uses thereof SG11202008767XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647556P 2018-03-23 2018-03-23
US201862667170P 2018-05-04 2018-05-04
PCT/US2019/023693 WO2019183551A1 (en) 2018-03-23 2019-03-22 Antibodies against mica and/or micb and uses thereof

Publications (1)

Publication Number Publication Date
SG11202008767XA true SG11202008767XA (en) 2020-10-29

Family

ID=66041791

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008767XA SG11202008767XA (en) 2018-03-23 2019-03-22 Antibodies against mica and/or micb and uses thereof

Country Status (16)

Country Link
US (2) US11242393B2 (en)
EP (1) EP3768715A1 (en)
JP (1) JP7351845B2 (en)
KR (1) KR20200135830A (en)
CN (1) CN111886256A (en)
AU (1) AU2019236865A1 (en)
BR (1) BR112020018539A2 (en)
CA (1) CA3093407A1 (en)
CL (1) CL2020002446A1 (en)
CO (1) CO2020013089A2 (en)
IL (1) IL277287A (en)
MX (1) MX2020009861A (en)
PE (1) PE20210665A1 (en)
SG (1) SG11202008767XA (en)
TW (1) TW202003565A (en)
WO (1) WO2019183551A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3532091A2 (en) * 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
EP3831849A1 (en) * 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
CN116547301A (en) 2020-08-10 2023-08-04 先天制药公司 Cell surface MICA and MICB detection using antibodies
JP2024501029A (en) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Subcutaneous administration of PD1/PD-L1 antibodies
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody compositions and methods of use thereof
CN115611982B (en) * 2021-07-14 2024-05-10 浙江大学 Monoclonal antibody of anti-human MICA/Bα3 region and application thereof
CN113637077B (en) * 2021-10-14 2021-12-24 尚健单抗（北京）生物技术有限公司 Antibody for resisting MICA and application thereof
CN114369162B (en) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 Antibodies and uses thereof
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024026414A1 (en) * 2022-07-28 2024-02-01 Cullinan Mica Corporation Anti-mica/b antibodies with enhanced effector function and methods of use

Family Cites Families (300)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
CA2156924A1 (en) 1993-12-27 1995-07-06 Ton That Hai Water soluble non-immunogenic polyamide cross-linking agents
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
JP2001502325A (en) 1996-10-11 2001-02-20 ブリストル―マイヤーズ・スクイブ・カンパニー Methods and compositions for immunomodulation
CA2275141A1 (en) 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
DE19821060A1 (en) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let T cell co-stimulating polypeptide, monoclonal antibodies, and the production and use thereof
DE59813875D1 (en) 1997-09-23 2007-02-22 Bundesrepublik Deutschland Let KO-STIMULATING POLYPEPTIDE OF T-CELLS, MONOCLONAL ANTIBODIES AND THE PREPARATION AND THEIR USE
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK2180007T4 (en) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
RS51309B (en) 1998-12-23 2010-12-31 Pfizer Inc. Human monoclonal antibodies to ctla-4
KR101077001B1 (en) 1999-01-15 2011-10-26 제넨테크, 인크. Polypeptide Variants with Altered Effector Function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (en) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
DK2283866T3 (en) 1999-06-25 2015-05-18 Genentech Inc METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CN1371416B (en) 1999-08-24 2012-10-10 梅达里克斯公司 Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
ATE336514T1 (en) 2000-02-11 2006-09-15 Merck Patent Gmbh INCREASE THE CIRCULATION HALF-LIFE OF ANTIBODIES-BASED FUSION PROTEINS
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
KR100857943B1 (en) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 Transgenic Transchromosomal Rodents for Making Human Antibodies
JP2004532038A (en) 2001-05-17 2004-10-21 ディヴァーサ コーポレイション Application of novel antigen-binding molecules to therapeutic, diagnostic, prophylactic, enzymatic, industrial and agricultural fields, and methods for producing and screening novel antigen-binding molecules therefor
IL154183A0 (en) 2001-05-31 2003-07-31 Medarex Inc Cytotoxins, prodrugs, linkers and stabilizers useful therefor
KR100988949B1 (en) 2001-10-25 2010-10-20 제넨테크, 인크. Glycoprotein compositions
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
EP1578923A4 (en) 2002-04-22 2009-01-21 Hutchinson Fred Cancer Res Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
EP1525223B1 (en) 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) receptor agonists and therapeutic use
JP2006500921A (en) 2002-07-30 2006-01-12 ブリストル−マイヤーズ　スクイブ　カンパニー Humanized antibody against human 4-1BB
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
CN101987871A (en) 2002-09-27 2011-03-23 赞科股份有限公司 Optimized fc variants and methods for their generation
DE60334141D1 (en) 2002-10-15 2010-10-21 Facet Biotech Corp CHANGE OF FcRn BINDING SAFFINITIES OR SERUM HALF TIMES OF ANTIBODIES BY MUTAGENESIS
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
PL1603541T5 (en) 2003-03-05 2013-06-28 Halozyme Inc SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
MXPA05013923A (en) 2003-07-02 2006-08-11 Univ Genova Compositions and methods for regulating nk cell activity.
BRPI0412890B8 (en) 2003-07-24 2021-05-25 Innate Pharma method of selecting an anti-kir2dl1 antibody or antigen-binding antibody fragment
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
DK1706424T3 (en) 2004-01-12 2009-11-02 Applied Molecular Evolution FC region variants
CA2561264A1 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
US7517903B2 (en) 2004-05-19 2009-04-14 Medarex, Inc. Cytotoxic compounds and conjugates
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US7740847B2 (en) 2004-08-04 2010-06-22 Applied Molecular Evolution, Inc. Variant Fc regions
NO346624B1 (en) 2004-12-28 2022-11-07 Univ Di Genova Monoclonal antibody against NKG2A
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
PT1836225E (en) 2005-01-06 2012-01-10 Novo Nordisk As Kir-binding agents and methods of use thereof
JP5249587B2 (en) 2005-02-18 2013-07-31 メダレックス， インク． Monoclonal antibody against prostate specific membrane antigen (PSMA) lacking fucosyl residues
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
ES2427646T5 (en) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies against programmed death 1 (PD1) and methods for the treatment of cancer through the use of anti-PD-1 antibodies alone or in combination with other immunotherapeutic agents
CN101212967A (en) 2005-05-10 2008-07-02 因塞特公司 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
PL2279758T3 (en) 2005-06-16 2015-07-31 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
MX2007015942A (en) 2005-07-01 2008-03-07 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1).
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
EP1934260B1 (en) 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
WO2007051081A1 (en) 2005-10-26 2007-05-03 Medarex, Inc. Methods and compounds for preparing cc-1065 analogs
US20070248607A1 (en) 2005-11-03 2007-10-25 Thomas Spies Negative immunomodulation of immune responses by nkg2d-positive cd4+ cells
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007084672A2 (en) 2006-01-17 2007-07-26 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
DK2426150T3 (en) 2006-06-30 2018-01-22 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
CL2007002650A1 (en) 2006-09-19 2008-02-08 Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036981A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Research, Inc. Methods for treating mica-related disorders
TWI412367B (en) 2006-12-28 2013-10-21 Medarex Llc Chemical linkers and cleavable substrates and conjugates thereof
ES2579768T3 (en) 2007-01-11 2016-08-16 Novo Nordisk A/S Anti-KIR antibodies, formulations and uses thereof
JP2010519310A (en) 2007-02-21 2010-06-03 メダレックス インコーポレイテッド Chemical linker having a single amino acid and complex thereof
AR061248A1 (en) * 2007-02-26 2008-08-13 Monsanto Technology Llc CHLOROPLASTIC TRANSIT PEPTIDES FOR THE EFFICIENT ADDRESS OF DMO AND ITS USES
CA2685056C (en) 2007-04-23 2015-08-25 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
CN101861168B (en) 2007-05-07 2014-07-02 米迪缪尼有限公司 Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2008278814A (en) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk Release of immunoregulation by agonistic anti-human gitr antibody, and application thereof
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
JP5932217B2 (en) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Combination therapy using GITR binding molecules
DE102007036200A1 (en) 2007-08-02 2009-02-05 Knorr-Bremse Systeme für Nutzfahrzeuge GmbH Inductive displacement or rotation angle sensor with shielding plate arranged between two coils
EP2195017B1 (en) 2007-10-01 2014-10-22 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
US20090181037A1 (en) 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
CL2008003526A1 (en) 2007-11-30 2010-01-11 Medarex Inc Antibody-associated molecule conjugate comprising a human monoclonal anti human b7-h4 / 08e / b7x / b7s1 / bl-cam / b3 / leu-14 / lyb-8 antibody; composition comprising it; in vitro method of inhibition of tumor cell expressing b7-h4 / 08e / b7x / b7s1 / bl-cam / b3 / leu-14 / lyb-8; and use to treat cancer.
JP5583592B2 (en) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション IDO inhibitor
CA2712220A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
US8182809B1 (en) * 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
HUE034832T2 (en) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
AU2010297580B2 (en) 2009-09-22 2014-07-31 Probiogen Ag Process for producing molecules containing specialized glycan structures
CN102740887B (en) 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 Combination immunotherapy for the treatment of cancer
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
ES2646863T3 (en) 2009-11-24 2017-12-18 Medimmune Limited B7-H1 specific binding agents
BR112012013717B1 (en) 2009-12-10 2020-01-28 Hoffmann La Roche antibodies binding to human csf-1r, pharmaceutical composition and uses of the antibody
CN104131035A (en) 2009-12-10 2014-11-05 瑞泽恩制药公司 Mice that make heavy chain antibodies
HUE026229T2 (en) 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
KR101656548B1 (en) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 Antibodies against human csf-1r and uses thereof
KR101647871B1 (en) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 Antibodies against human csf-1r and uses thereof
MX339621B (en) 2010-04-13 2016-06-02 Celldex Therapeutics Inc * Antibodies that bind human cd27 and uses thereof.
ES2706412T3 (en) 2010-05-04 2019-03-28 Five Prime Therapeutics Inc Antibodies that bind to CSF1R
EP3363499A1 (en) 2010-06-11 2018-08-22 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
NZ627119A (en) 2010-06-22 2015-05-29 Regeneron Pharma Hybrid light chain mice
MY171312A (en) 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
WO2012065086A1 (en) 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
JP6224457B2 (en) 2010-11-22 2017-11-01 イネイト・ファルマ・ソシエテ・アノニム NK cell regulatory treatment and malignant blood disease treatment method
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
JP6220774B2 (en) 2011-03-31 2017-10-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Antibodies against ICOS and uses thereof
NO2694640T3 (en) 2011-04-15 2018-03-17
MX338353B (en) 2011-04-20 2016-04-13 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1.
CA2837184C (en) 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN103946238B (en) 2011-08-23 2016-10-12 德克萨斯州立大学董事会 Anti-OX40 antibody and the method using it
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
BR112014011144A2 (en) 2011-11-09 2017-05-16 Bristol Myers Squibb Co treatment of hematological malignancies with an anti-cxcr4 antibody
JP6138813B2 (en) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Anti-PD-L1 antibody and use thereof
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
JP6405242B2 (en) 2012-02-07 2018-10-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． MICA binder
AR090263A1 (en) 2012-03-08 2014-10-29 Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
BR112014028013A2 (en) 2012-05-11 2018-02-27 Five Prime Therapeutics Inc methods for treating a condition associated with rheumatoid arthritis, rheumatoid arthritis, skin lesions, lupus nephritis, lupus, an inflammatory condition, cd16 + disorder, method for reducing the number of cd16 + monocytes, methods for slowing the progression of a renal condition, rag and bone loss
EP2850102A1 (en) 2012-05-15 2015-03-25 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20220084444A (en) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Antigen binding proteins that bind pd-l1
KR101566538B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th17 cell and use thereof
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
CA2882804A1 (en) 2012-08-31 2014-03-06 Brian Wong Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
ES2643887T3 (en) 2012-10-02 2017-11-27 Bristol-Myers Squibb Company Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
EA201591559A1 (en) 2013-03-15 2016-03-31 Дана-Фарбер Кэнсер Инститьют, Инк. THERAPEUTIC PEPTIDES
WO2014140884A2 (en) 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Methods and devices for removal of immunosuppressive ligands
EP2970490A4 (en) 2013-03-15 2017-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
MD20180107A2 (en) 2013-03-18 2019-06-30 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
CN105339389B (en) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 Antibodies against programmed death-1 (PD-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
EP3016683B1 (en) 2013-07-05 2020-06-24 University of Washington through its Center for Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
JP6623353B2 (en) 2013-09-13 2019-12-25 ベイジーン スウィッツァーランド ゲーエムベーハー Anti-PD-1 antibodies and their use for therapy and diagnosis
RS64268B1 (en) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
BR112016012358A2 (en) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc therapeutic peptides
CN105026428B (en) 2013-12-12 2018-01-16 上海恒瑞医药有限公司 PD l antibody, its antigen-binding fragment and its medical usage
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
DK3134123T3 (en) 2014-02-21 2021-04-06 Nektar Therapeutics India Pvt Ltd IL-2R BETA SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
MX2016012779A (en) 2014-03-31 2017-04-27 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists.
PT3126394T (en) 2014-03-31 2019-12-19 Hoffmann La Roche Anti-ox40 antibodies and methods of use
PT3148579T (en) 2014-05-28 2021-03-11 Ludwig Inst For Cancer Res Ltd Anti-gitr antibodies and methods of use thereof
DK3151921T3 (en) 2014-06-06 2019-12-02 Bristol Myers Squibb Co ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR CANCER FACTOR RECEPTORS (GITR) AND APPLICATIONS THEREOF
SG11201701385WA (en) 2014-08-28 2017-03-30 Academisch Ziekenhuis Leiden Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
EP3193929B1 (en) 2014-09-16 2019-06-12 Innate Pharma Treatment regimens using anti-nkg2a antibodies
CN107001466B (en) 2014-09-16 2021-10-26 依奈特制药公司 Neutralization of inhibitory pathways in lymphocytes
TW201619200A (en) 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
JP6709215B2 (en) 2014-10-27 2020-06-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ Anti-TIM-3 antibody
EP3632935A1 (en) 2014-11-06 2020-04-08 F. Hoffmann-La Roche AG Anti-tim3 antibodies and methods of use
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
MA40662B1 (en) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Antibodies against tigit
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
MA41414A (en) 2015-01-28 2017-12-05 Centre Nat Rech Scient ICOS AGONIST BINDING PROTEINS
CN107530424A (en) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 For NKG2D and the bivalent antibody of tumor associated antigen
TW201639888A (en) 2015-03-06 2016-11-16 索倫多醫療公司 Antibody therapeutics that bind TIM3
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
PT3273992T (en) 2015-03-23 2020-08-21 Jounce Therapeutics Inc Antibodies to icos
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
MA41867A (en) 2015-04-01 2018-02-06 Anaptysbio Inc T-CELL IMMUNOGLOBULIN AND MUCINE PROTEIN 3 ANTIBODIES (TIM-3)
EP3303394B1 (en) 2015-05-29 2020-04-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
CN107810011A (en) 2015-06-08 2018-03-16 豪夫迈·罗氏有限公司 Use the method for anti-OX40 antibodies for treating cancer
EP3307777A4 (en) 2015-06-11 2019-02-13 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
DK3328419T3 (en) 2015-07-30 2021-10-11 Macrogenics Inc PD-1 BINDING MOLECULES AND METHODS FOR USING IT
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
JP6883579B2 (en) 2015-08-11 2021-06-09 ウーシー バイオロジクス（ケイマン）インコーポレイテッド New anti-PD-1 antibody
US11014983B2 (en) 2015-08-20 2021-05-25 Sutro Biopharma, Inc. Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
AR105654A1 (en) 2015-08-24 2017-10-25 Lilly Co Eli ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH)
EA201890630A1 (en) 2015-09-01 2018-10-31 Эйдженус Инк. ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
RU2732591C2 (en) 2015-09-25 2020-09-21 Дженентек, Инк. Anti-tigit antibodies and methods of using
SI3356411T1 (en) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
WO2017055399A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Cellular based fret assay for the determination of simultaneous binding
CN114380908B (en) 2015-10-15 2023-03-17 苏州丁孚靶点生物技术有限公司 anti-OX40 antibodies and uses thereof
PL3370768T3 (en) 2015-11-03 2022-06-13 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017096281A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
US11447557B2 (en) 2015-12-02 2022-09-20 Agenus Inc. Antibodies and methods of use thereof
CA3006963A1 (en) 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
MY196756A (en) 2015-12-14 2023-05-03 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
CN108697776A (en) 2016-01-11 2018-10-23 阿尔莫生物科技股份有限公司 Interleukin-10 in generating antigentic specificity CD8+T cells and its application method
CN111385767A (en) 2016-02-02 2020-07-07 华为技术有限公司 Method for determining transmission power, user equipment and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017134292A1 (en) 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
KR20180118673A (en) 2016-03-15 2018-10-31 이나뜨 파르마 Anti-MICA antibody
DK3443009T3 (en) 2016-04-12 2021-12-13 Symphogen As ANTI-HOUR-3 ANTIBODIES AND COMPOSITIONS
SG11201810023QA (en) 2016-05-27 2018-12-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
JP7261379B2 (en) 2016-06-20 2023-04-20 カイマブ・リミテッド Anti-PD-L1 antibody
CN117683135A (en) 2016-07-14 2024-03-12 百时美施贵宝公司 Antibodies against TIM3 and uses thereof
JOP20190013A1 (en) 2016-08-25 2019-01-31 Lilly Co Eli Anti-tim-3 antibodies
SG11201901548SA (en) 2016-08-26 2019-03-28 Beigene Ltd Anti-tim-3 antibodies and use thereof
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
JP2020509037A (en) 2017-02-28 2020-03-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Use of an anti-CTLA-4 antibody with enhanced ADCC to enhance the immune response to a vaccine
SG11201908396PA (en) * 2017-03-31 2019-10-30 Bristol Myers Squibb Co Methods of treating tumor
EP3694884A1 (en) * 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
CA3089478A1 (en) 2018-01-25 2019-08-01 Pdi Therapeutics, Inc. Mica/b antibodies and methods of use
JP2021519771A (en) * 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ How to treat a tumor

Also Published As

Publication number Publication date
US20190315870A1 (en) 2019-10-17
JP2021518140A (en) 2021-08-02
PE20210665A1 (en) 2021-03-31
KR20200135830A (en) 2020-12-03
MX2020009861A (en) 2020-10-08
BR112020018539A2 (en) 2020-12-29
JP7351845B2 (en) 2023-09-27
US20220281980A1 (en) 2022-09-08
CN111886256A (en) 2020-11-03
US11242393B2 (en) 2022-02-08
CA3093407A1 (en) 2019-09-26
AU2019236865A1 (en) 2020-10-01
TW202003565A (en) 2020-01-16
CL2020002446A1 (en) 2021-03-05
IL277287A (en) 2020-10-29
EP3768715A1 (en) 2021-01-27
CO2020013089A2 (en) 2020-10-30
WO2019183551A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL277287A (en) Antibodies against mica and/or micb and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
IL279455A (en) Anti-pd-1 antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
SG11202101675UA (en) Anti-bcma single domain antibodies and application thereof
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
IL276675A (en) Anti-pd-1 antibodies and uses thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof
IL280281A (en) Anti-cd40 antibodies and uses thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL283926A (en) Anti-alpha-synuclein antibodies and uses thereof
IL291546A (en) Anti-kir3dl3 antibodies and uses thereof
IL291280A (en) Anti-cd371 antibodies and uses thereof
IL283890A (en) Anti-periostin antibodies and uses thereof